Lilly And AC Immune Announce License And Collaboration Agreement To Focus On Potential Alzheimers Treatment; AC Immune To Receive CHF80M Upfront And IS Eligible For Additional Milestones While Lilly Will Purchase A $50M Note Convertible Equity Position
Benzinga Newsdesk